Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
Advanced Science · 2025-02 · 12 (5)
DOI: 10.1002/advs.202413103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 10.12.2024. Verfasst von Yilan Yang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, No.270 Dong'an Road, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Cholesterol, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
Inhibitors targeting cyclin‐dependent kinases 4 and 6 (CDK4/6) to block cell cycle progression have been effective in treating hormone receptor‐positive breast cancer, but triple‐negative breast cancer (TNBC) remains largely resistant, limiting their clinical applicability. The study reveals that transcription regulator cyclin‐dependent kinase7 (CDK7) is a promising target to circumvent TNBC's inherent resistance to CDK4/6 inhibitors. Combining CDK4/6 and CDK7 inhibitors significantly enhances therapeutic effectiveness, leading to a marked decrease in cholesterol biosynthesis within cells. This effect is achieved through reduced activity of the transcription factor forkhead box M1 (FOXM1), which normally increases cholesterol production by inducing SREBF1 expression. Furthermore, this dual inhibition strategy attenuates the recruitment of sterol regulatory element binding transcription factor 1 (SREBP1) and p300 to genes essential for cholesterol synthesis, thus hindering tumor growth. This research is corroborated by an in‐house cohort showing lower survival rates in TNBC patients with higher cholesterol production gene activity. This suggests a new treatment approach for TNBC by simultaneously targeting CDK4/6 and CDK7, warranting additional clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, No.270 Dong'an Road, Shanghai, 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, No.270 Dong'an Road, Shanghai, 200032, China.
- Shanghai Clinical Research Center for Radiation Oncology, No.270 Dong'an Road, Shanghai, 200032, China.
- Shanghai Key Laboratory of Radiation Oncology, No.270 Dong'an Road, Shanghai, 200032, China.
- Radiation Oncology Center, Huashan Hospital, No.12 Wulumuqi Middle Road, Shanghai, 200040, China.
- Department of Radiation Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No.1630 Dongfang Road, Shanghai, 200127, China.
ORCID-Profile: Xiaomao Guo
Förderung
- National Natural Science Foundation of China
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
Zitieren
APA
Yang, Y., Liao, J., Pan, Z., Meng, J., Zhang, L., Shi, W., Wang, X., Zhang, X., Zhou, Z., Luo, J., Chen, X., Yang, Z., Mei, X., Ma, J., Zhang, Z., Jiang, Y. Z., Shao, Z. M., Chen, F. X., Yu, X., & Guo, X. (2025). Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism. Advanced Science, 12(5). https://doi.org/10.1002/advs.202413103
Vancouver
Yang Y, Liao J, Pan Z, Meng J, Zhang L, Shi W, et al. Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism. Advanced Science. 2025;12(5). doi:10.1002/advs.202413103
BibTeX
@article{Yang2025,
author = {Yang, Yilan and Liao, Jiatao and Pan, Zhe and Meng, Jin and Zhang, Li and Shi, Wei and Wang, Xiaofang and Zhang, Xiaomeng and Zhou, Zhirui and Luo, Jurui and Chen, Xingxing and Yang, Zhaozhi and Mei, Xin and Ma, Jinli and Zhang, Zhen and Jiang, Yi-Zhou and Shao, Zhi-Min and Chen, Fei Xavier and Yu, Xiaoli and Guo, Xiaomao},
title = {Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {5},
doi = {10.1002/advs.202413103}
}
EUVIMED